Objective:To investigate the effects of different doses of dexmedetomidine (DEX) pretreatment combined with intraoperative nalbuphine anesthesia on hemodynamics and recovery quality in patients undergoing transabdominal myomectomy.Methods:A total of 100 patients scheduled for elective transabdominal myomectomy at Mingguang People’s Hospital were selected from Jan. 2021 to Jan. 2025 were randomly divided into four groups ( n=25) : the control group (group C) received saline infusion before anesthesia induction; the low-dose (group D1), medium-dose (group D2), and high-dose DEX groups (group D3) received 0.5, 1.0, and 1.5 μg/kg DEX, respectively. All patients followed a unified anesthesia induction and maintenance protocol. Intraoperative hemodynamic parameters (MAP, HR) were monitored, and postoperative recovery time, Ramsay sedation score, and VAS pain score were assessed. Adverse reactions were recorded. Results:The medium-dose DEX group (group D2) demonstrated the best performance in hemodynamic stability, recovery quality, and adverse reaction control. Group D2 showed the smallest fluctuations in MAP and HR, the shortest recovery time (12.31±2.11 min), the lowest postoperative VAS score (2.11±0.82 points), and the lowest incidence of postoperative agitation (4.00%). The high-dose DEX group (group D3) exhibited excessive inhibition, leading to significantly higher incidences of hypotension (24.00%) and bradycardia (24.00%), as well as prolonged recovery time (20.12±3.52 min). The low-dose DEX group (group D1) showed limited effects, with no significant differences compared to the control group.Conclusion:Pretreatment with 1.0 μg/kg DEX combined with nalbuphine anesthesia provides the best clinical outcomes in transabdominal myomectomy, effectively stabilizing hemodynamics, optimizing recovery quality, and reducing adverse reactions. Insufficient or excessive doses may diminish its benefits.

Objective:To investigate the effects of different doses of dexmedetomidine (DEX) pretreatment combined with intraoperative nalbuphine anesthesia on hemodynamics and recovery quality in patients undergoing transabdominal myomectomy.Methods:A total of 100 patients scheduled for elective transabdominal myomectomy at Mingguang People’s Hospital were selected from Jan. 2021 to Jan. 2025 were randomly divided into four groups ( n=25) : the control group (group C) received saline infusion before anesthesia induction; the low-dose (group D1), medium-dose (group D2), and high-dose DEX groups (group D3) received 0.5, 1.0, and 1.5 μg/kg DEX, respectively. All patients followed a unified anesthesia induction and maintenance protocol. Intraoperative hemodynamic parameters (MAP, HR) were monitored, and postoperative recovery time, Ramsay sedation score, and VAS pain score were assessed. Adverse reactions were recorded. Results:The medium-dose DEX group (group D2) demonstrated the best performance in hemodynamic stability, recovery quality, and adverse reaction control. Group D2 showed the smallest fluctuations in MAP and HR, the shortest recovery time (12.31±2.11 min), the lowest postoperative VAS score (2.11±0.82 points), and the lowest incidence of postoperative agitation (4.00%). The high-dose DEX group (group D3) exhibited excessive inhibition, leading to significantly higher incidences of hypotension (24.00%) and bradycardia (24.00%), as well as prolonged recovery time (20.12±3.52 min). The low-dose DEX group (group D1) showed limited effects, with no significant differences compared to the control group.Conclusion:Pretreatment with 1.0 μg/kg DEX combined with nalbuphine anesthesia provides the best clinical outcomes in transabdominal myomectomy, effectively stabilizing hemodynamics, optimizing recovery quality, and reducing adverse reactions. Insufficient or excessive doses may diminish its benefits.